Hepatoid Adenocarcinoma of the Lung Responsive to Frontline Combination Chemotherapy With Immunotherapy: Case Report [0.03%]
对一线免疫联合化疗有反应的肺肝样腺癌：病例报告
Galina G Lagos,Jarett L Feldman,Anjali Saqi et al.
Galina G Lagos et al.
Hepatoid adenocarcinoma of the lung (HAL) is a rare extrahepatic tumor characterized by histologic features of hepatocellular carcinoma. The standard treatment for nonresectable HAL has not been established, though traditionally, these tumo...
Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde [0.03%]
组织学转换的旋转门 - 肿瘤异质性使EGFR突变型肺腺癌的管理复杂化：一个化身博士与海德先生的病例
Michael Wysota,Saeed Asiry,Yitzhak Goldstein et al.
Michael Wysota et al.
BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma [0.03%]
具有BRAF突变的肺朗格罕细胞增生症似早期KRAS突变型肺癌再发表現形式
Stephanie L Alden,Scott J Swanson,Mizuki Nishino et al.
Stephanie L Alden et al.
Utility of Newly Proposed Grading System From International Association for the Study of Lung Cancer for Invasive Lung Adenocarcinoma [0.03%]
国际肺癌研究协会新提出的侵袭性肺腺癌分级系统的作用分析
Atsushi Kagimoto,Yasuhiro Tsutani,Takahiro Kambara et al.
Atsushi Kagimoto et al.
Introduction: The International Association for the Study of Lung Cancer proposed a new grading criteria for invasive adenocarcinoma. However, its utility has not been validated. ...
STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib [0.03%]
STRN-ALK，一种对Alectinib有反应的新型框内融合蛋白
Misako Nagasaka,Nagaratna Sarvadevabatla,Shawn Iwata et al.
Misako Nagasaka et al.
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study [0.03%]
罗西替尼与化疗在EGFR突变型NSCLC患者中的有效性和安全性：TIGER-3，一项第三阶段随机研究的结果
James Chih-Hsin Yang,Karen L Reckamp,Young-Chul Kim et al.
James Chih-Hsin Yang et al.
Introduction: The TIGER-3 (NCT02322281) study was initiated to compare the efficacy and safety of rociletinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR T790M and common EGFR-activating mut...
A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib [0.03%]
下一代序列中发现的罕见LOC285000-ALK-NCK2基因融合肺癌腺癌，并对克唑替尼有长期疗效一例报告
Min Zhang,Huan Zhou,Dan Liu et al.
Min Zhang et al.
Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare LOC285000-ALK-NCK2 gene fusion with response to crizotinib treatment; the patient ...
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414) [0.03%]
达特鲁单抗联合阿特珠单抗治疗先前接受过治疗的晚期或转移性非小细胞肺癌：随机、开放标签、II期研究（LUC2001 JNJ-54767414）的简短报告
Rathi N Pillai,Suresh S Ramalingam,Meena Thayu et al.
Rathi N Pillai et al.
Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC. Preclinical studies indicate that ...
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies [0.03%]
JNJ-64041757（JNJ-757），一种用于NSCLC患者的活的，减毒的双基因缺失李斯特菌单核细胞增多症为基础的免疫疗法：两项1期研究的结果
Julie R Brahmer,Melissa L Johnson,Manuel Cobo et al.
Julie R Brahmer et al.
Introduction: JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted Listeria monocytogenes-based immunotherapy expressing human mesothelin. JNJ-757 was evaluated in patients with advanced NSCLC as monotherapy (phas...
The Reproducibility of Histopathologic Assessments of Programmed Cell Death-Ligand 1 Using Companion Diagnostics in NSCLC [0.03%]
使用伴随机诊断评估NSCLC中程序性细胞死亡配体1的可重复性
Pei Yuan,Changyuan Guo,Lin Li et al.
Pei Yuan et al.
Introduction: Accurate results on the status of programmed cell death-ligand 1 (PD-L1) rely on not only the quality of immunohistochemistry testing but also the accuracy of the pathologic assessments. We explored the intr...